Curis Inc (CRIS)
11.80
-0.80
(-6.35%)
USD |
NASDAQ |
May 17, 16:00
11.80
0.00 (0.00%)
After-Hours: 20:00
Curis Cash from Financing (Quarterly): -2.406M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -2.406M |
| December 31, 2023 | -2.118M |
| September 30, 2023 | 12.56M |
| June 30, 2023 | -0.852M |
| March 31, 2023 | -2.006M |
| December 31, 2022 | -1.388M |
| September 30, 2022 | 4.662M |
| June 30, 2022 | -0.759M |
| March 31, 2022 | -1.648M |
| December 31, 2021 | -1.312M |
| September 30, 2021 | -0.956M |
| June 30, 2021 | -0.575M |
| March 31, 2021 | -1.329M |
| December 31, 2020 | 165.24M |
| September 30, 2020 | 5.82M |
| June 30, 2020 | 16.48M |
| March 31, 2020 | 1.277M |
| December 31, 2019 | -1.061M |
| September 30, 2019 | -0.611M |
| June 30, 2019 | -0.82M |
| March 31, 2019 | 25.76M |
| December 31, 2018 | -1.639M |
| September 30, 2018 | -1.36M |
| June 30, 2018 | -1.147M |
| March 31, 2018 | -1.815M |
| Date | Value |
|---|---|
| December 31, 2017 | -1.473M |
| September 30, 2017 | 34.71M |
| June 30, 2017 | -0.505M |
| March 31, 2017 | 31.51M |
| December 31, 2016 | 0.692M |
| September 30, 2016 | -0.615M |
| June 30, 2016 | -0.322M |
| March 31, 2016 | -1.121M |
| December 31, 2015 | -0.366M |
| September 30, 2015 | -1.108M |
| June 30, 2015 | -0.9223M |
| March 31, 2015 | 64.06M |
| December 31, 2014 | -0.747M |
| September 30, 2014 | -0.8138M |
| June 30, 2014 | 0.0764M |
| March 31, 2014 | 0.1804M |
| December 31, 2013 | 7.254M |
| September 30, 2013 | 9.819M |
| June 30, 2013 | 2.892M |
| March 31, 2013 | 0.0362M |
| December 31, 2012 | 30.01M |
| September 30, 2012 | 1.260M |
| June 30, 2012 | 1.274M |
| March 31, 2012 | 3.276M |
| December 31, 2011 | 0.5998M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-2.406M
Minimum
Mar 2024
165.24M
Maximum
Dec 2020
9.410M
Average
-0.836M
Median
Cash from Financing (Quarterly) Benchmarks
| AIM ImmunoTech Inc | 0.147M |
| Perspective Therapeutics Inc | 166.33M |
| Protalix BioTherapeutics Inc | 0.00 |
| Electromed Inc | 0.056M |
| Armata Pharmaceuticals Inc | 34.93M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -13.23M |
| Cash from Investing (Quarterly) | 18.91M |
| Free Cash Flow | -39.47M |
| Free Cash Flow Per Share (Quarterly) | -2.288 |
| Free Cash Flow to Equity (Quarterly) | -13.23M |
| Free Cash Flow Yield | -60.49% |